CN106232140A - 通过施用il‑4r拮抗剂治疗或预防哮喘的方法 - Google Patents

通过施用il‑4r拮抗剂治疗或预防哮喘的方法 Download PDF

Info

Publication number
CN106232140A
CN106232140A CN201580020533.9A CN201580020533A CN106232140A CN 106232140 A CN106232140 A CN 106232140A CN 201580020533 A CN201580020533 A CN 201580020533A CN 106232140 A CN106232140 A CN 106232140A
Authority
CN
China
Prior art keywords
antibody
experimenter
antagonist
fab
maintenance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580020533.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·皮罗奇
F·斯科比尔兰达
Y·李
N·格雷汉姆
S·P·温斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Drugmaker Of Regenerating
Sanofi SA
Original Assignee
First Drugmaker Of Regenerating
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51570453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106232140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by First Drugmaker Of Regenerating, Sanofi SA filed Critical First Drugmaker Of Regenerating
Publication of CN106232140A publication Critical patent/CN106232140A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580020533.9A 2014-02-21 2015-02-20 通过施用il‑4r拮抗剂治疗或预防哮喘的方法 Pending CN106232140A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943019P 2014-02-21 2014-02-21
US61/943,019 2014-02-21
EP14306413 2014-09-15
EP14306413.7 2014-09-15
US201462077669P 2014-11-10 2014-11-10
US62/077,669 2014-11-10
PCT/US2015/016852 WO2015127229A1 (en) 2014-02-21 2015-02-20 Methods for treating or preventing asthma by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
CN106232140A true CN106232140A (zh) 2016-12-14

Family

ID=51570453

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580020533.9A Pending CN106232140A (zh) 2014-02-21 2015-02-20 通过施用il‑4r拮抗剂治疗或预防哮喘的方法

Country Status (15)

Country Link
US (3) US10137193B2 (https=)
EP (3) EP3107575B1 (https=)
JP (3) JP6673840B2 (https=)
KR (4) KR20220029765A (https=)
CN (1) CN106232140A (https=)
AU (3) AU2015218808B2 (https=)
CA (2) CA3249780A1 (https=)
ES (2) ES2897631T3 (https=)
HU (1) HUE065844T2 (https=)
IL (1) IL315136A (https=)
MX (2) MX384192B (https=)
PL (2) PL3107575T3 (https=)
PT (2) PT3973987T (https=)
RU (1) RU2713406C2 (https=)
WO (1) WO2015127229A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020048312A1 (zh) * 2018-09-04 2020-03-12 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
WO2020135710A1 (zh) * 2018-12-27 2020-07-02 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
CN111526920A (zh) * 2017-10-30 2020-08-11 赛诺菲生物技术公司 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
CN115175700A (zh) * 2019-07-16 2022-10-11 赛诺菲生物技术公司 用于通过施用il-4r拮抗剂治疗或预防哮喘的方法
CN115666641A (zh) * 2020-06-16 2023-01-31 三生国健药业（上海）股份有限公司 一种稳定的抗IL-4Rα单克隆抗体液体制剂
US11845800B2 (en) 2012-08-21 2023-12-19 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
WO2025067567A1 (zh) * 2023-09-28 2025-04-03 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN111437387B (zh) * 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
EP4345110A3 (en) 2016-09-22 2024-06-12 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
US11154621B2 (en) 2017-06-27 2021-10-26 Ohio State Innovation Foundation Liponucleotide-based therapy for COPD
US11850283B2 (en) 2017-06-27 2023-12-26 Ohio State Innovation Foundation Liponucleotide-based therapy for asthma
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
AR115730A1 (es) 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
US20210000949A1 (en) * 2019-05-01 2021-01-07 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
WO2022031956A1 (en) * 2020-08-05 2022-02-10 Knopp Biosciences Llc Use of dexpramipexole for the treatment of moderate to severe asthma
JP2023544406A (ja) * 2020-10-05 2023-10-23 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法
TW202313692A (zh) * 2021-08-26 2023-04-01 大陸商正大天晴藥業集團股份有限公司 抗ｉｌ４ｒ抗體的藥物組成物及其用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
EP2441838A3 (en) * 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101759457B1 (ko) * 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
AU2009322556A1 (en) 2008-12-01 2011-07-21 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012049278A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US20140328839A1 (en) * 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
CA3079946A1 (en) * 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP2023544406A (ja) 2020-10-05 2023-10-23 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SALLY WENZEL等: "Dupilumab in Persistent Asthma with Elevated Eosinophil Levels", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
无: "Immunoglobulin, anti-(human interleukin 4 receptor α) (human REGN668 heavy chain), disulfide with human REGN668 .kappa.-chain, dimer (CA INDEX NAME)", 《STN》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845800B2 (en) 2012-08-21 2023-12-19 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN111526920A (zh) * 2017-10-30 2020-08-11 赛诺菲生物技术公司 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
WO2020048312A1 (zh) * 2018-09-04 2020-03-12 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
US11667717B2 (en) 2018-09-04 2023-06-06 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Antibodies binding to human IL-4R, preparation method therefor and use thereof
WO2020135710A1 (zh) * 2018-12-27 2020-07-02 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
CN115175700A (zh) * 2019-07-16 2022-10-11 赛诺菲生物技术公司 用于通过施用il-4r拮抗剂治疗或预防哮喘的方法
US12398212B2 (en) 2019-07-16 2025-08-26 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN115666641A (zh) * 2020-06-16 2023-01-31 三生国健药业（上海）股份有限公司 一种稳定的抗IL-4Rα单克隆抗体液体制剂
WO2025067567A1 (zh) * 2023-09-28 2025-04-03 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用

Also Published As

Publication number Publication date
KR20250154567A (ko) 2025-10-28
PT3973987T (pt) 2024-04-01
CA2940295A1 (en) 2015-08-27
EP3107575B1 (en) 2021-09-01
AU2020277191B2 (en) 2024-05-16
PT3107575T (pt) 2021-11-18
JP2023162343A (ja) 2023-11-08
JP7636487B2 (ja) 2025-02-26
US20150246119A1 (en) 2015-09-03
MX384192B (es) 2025-03-14
AU2015218808B2 (en) 2020-09-24
US20210322546A1 (en) 2021-10-21
RU2016136364A3 (https=) 2018-10-11
MX2016010854A (es) 2017-01-05
AU2020277191A1 (en) 2020-12-24
EP3107575A1 (en) 2016-12-28
US10137193B2 (en) 2018-11-27
JP7842268B2 (ja) 2026-04-07
EP3973987A1 (en) 2022-03-30
EP4382164A3 (en) 2024-08-07
AU2024203849A1 (en) 2024-06-27
AU2015218808A1 (en) 2016-09-22
KR102368450B1 (ko) 2022-02-28
IL315136A (en) 2024-10-01
PL3107575T3 (pl) 2022-01-17
ES2897631T3 (es) 2022-03-02
ES2977332T3 (es) 2024-08-22
HUE065844T2 (hu) 2024-06-28
EP3973987B1 (en) 2024-01-10
EP4382164A2 (en) 2024-06-12
RU2016136364A (ru) 2018-03-22
JP6673840B2 (ja) 2020-03-25
JP2017507139A (ja) 2017-03-16
JP2025072593A (ja) 2025-05-09
WO2015127229A1 (en) 2015-08-27
CA3249780A1 (en) 2026-03-02
KR20230167770A (ko) 2023-12-11
PL3973987T3 (pl) 2024-06-24
KR20220029765A (ko) 2022-03-08
RU2713406C2 (ru) 2020-02-05
MX2021008113A (es) 2021-10-13
KR20160113733A (ko) 2016-09-30
US20190125865A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
JP7636487B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
TWI656880B (zh) 投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法
TWI894144B (zh) 藉由投予il-33拮抗劑治療或預防哮喘之方法
TW202502819A (zh) 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
CN114786775A (zh) 通过施用il-33拮抗剂治疗copd的方法
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40110800A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK1231767B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
TWI721272B (zh) 投與il-4r拮抗劑以治療或預防氣喘之方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination